Results 141 to 150 of about 60,013 (197)

Potent Therapeutic Activity of NEO212 in Preclinical Models of Human and Canine Leukaemia and Lymphoma

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Haematological cancer types, such as leukaemia and lymphoma, represent diseases that are life‐threatening to canine and human patients alike, and better treatments are needed. We are developing a novel anticancer agent, NEO212, a conjugate of two cancer drugs, the alkylating agent temozolomide (TMZ) and the monoterpene perillyl alcohol (POH ...
Thomas C. Chen   +4 more
wiley   +1 more source

Technical considerations and review of urinary microRNAs as biomarkers for chronic kidney disease in dogs and cats

open access: yesVeterinary Clinical Pathology, EarlyView.
Abstract MicroRNAs (miRNAs or miRs) are small, non‐coding RNAs that play a crucial role in gene regulation, making them potential biomarkers for various diseases. In the field of veterinary medicine, there is a growing interest in exploring the diagnostic and therapeutic potential of miRNAs in kidney diseases affecting dogs and cats.
Candice P. Chu, Mary B. Nabity
wiley   +1 more source

Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client‐owned dogs: A multicentre, double‐masked, randomised, placebo‐controlled clinical trial

open access: yesVeterinary Dermatology, EarlyView.
Background – Inhibition of the Janus kinase (JAK) pathway is a well‐established option for canine atopic dermatitis (cAD). Objective – To evaluate the efficacy and safety of ilunocitinib, a novel JAK inhibitor for the control of pruritus and skin lesions in client‐owned dogs with cAD.
Sophie Forster   +5 more
wiley   +1 more source

Pediatric Voiding Dysfunction: Definitions and Management. [PDF]

open access: yesMedicina (Kaunas)
Lusnia C, DeMarco R, Sharadin C.
europepmc   +1 more source

Home - About - Disclaimer - Privacy